September 2007 – Phase 2 Clinical Trial in Acne Vulgaris Begins Enrollment

Posted in: News & Events
By Press Release
Sep 1, 2007 - 12:27:52 PM

For Immediate Release


September 2007 – Phase 2 Clinical Trial in Acne Vulgaris Begins Enrollment
 
AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9® as a topical agent for the treatment of acne. Two
Phase 1 human clinical trials have already been successfully completed.  Enrollment in a Phase 2 randomized, double-blinded, placebo-controlled 12-week dose-ranging study began in September 2007. The purpose of this Phase 2 study is to evaluate the safety and efficacy of ASC-J9® as a topical cream treatment of acne vulgaris.

Any patients with facial acne interested in enrolling in the study may contact Gloria Gosse at 201-587-0500, Ext. 3333.


 
Home | Corporate Overview | Product Pipeline | Science & Technology | News & Events | Contact Us | Privacy Policy